GEODE CAPITAL MANAGEMENT, LLC - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 48 filers reported holding CTI BIOPHARMA CORP in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$8,525,080
+74024.7%
2,029,780
+6.1%
0.00%
-50.0%
Q4 2022$11,501
-99.9%
1,913,754
+7.6%
0.00%0.0%
Q3 2022$10,353,000
+9.2%
1,778,969
+12.0%
0.00%
+100.0%
Q2 2022$9,483,000
+161.2%
1,588,547
+104.3%
0.00%
Q1 2022$3,631,000
+114.6%
777,616
+13.9%
0.00%
Q4 2021$1,692,000
-12.9%
682,626
+3.6%
0.00%
Q3 2021$1,943,000
+32.0%
658,826
+11.8%
0.00%
Q2 2021$1,472,000
+4.8%
589,150
+22.1%
0.00%
Q1 2021$1,404,000
+1.2%
482,648
+12.0%
0.00%
Q4 2020$1,388,000
+55.1%
431,081
+3.5%
0.00%
Q3 2020$895,000
+82.3%
416,437
-1.7%
0.00%
Q2 2020$491,000
+28.5%
423,585
+1.8%
0.00%
Q1 2020$382,000
-69.9%
416,013
-48.2%
0.00%
Q4 2019$1,268,000
+239.0%
803,486
+78.7%
0.00%
Q3 2019$374,000
-4.6%
449,754
-1.5%
0.00%
Q2 2019$392,000
-35.9%
456,654
-27.6%
0.00%
Q1 2019$612,000
-34.1%
631,113
-50.1%
0.00%
Q4 2018$928,000
-31.5%
1,265,454
+101.7%
0.00%
Q3 2018$1,355,000
-47.0%
627,513
+22.3%
0.00%
-100.0%
Q2 2018$2,555,000
+116.2%
513,223
+69.3%
0.00%
Q1 2018$1,182,000
+270.5%
303,229
+154.0%
0.00%
Q4 2017$319,000
-48.5%
119,387
-38.7%
0.00%
Q3 2017$620,000
+64.9%
194,685
+71.3%
0.00%
Q2 2017$376,000
-23.7%
113,682
-3.3%
0.00%
Q1 2017$493,000117,5200.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2017
NameSharesValueWeighting ↓
CAXTON CORP 3,749,890$12,075,0007.53%
Stonepine Capital Management, LLC 2,054,000$6,614,0005.06%
BVF INC/IL 6,929,690$22,314,0000.88%
Consonance Capital Management LP 2,512,800$8,091,0000.76%
Altium Capital Management LP 588,992$1,897,0000.71%
NEA Management Company, LLC 7,140,450$22,992,0000.61%
Ghost Tree Capital, LLC 750,000$2,415,0000.54%
Orbimed Advisors 9,520,600$30,656,0000.27%
One68 Global Capital, LLC 39,116$126,0000.25%
EAM Investors, LLC 240,108$773,0000.13%
View complete list of CTI BIOPHARMA CORP shareholders